Pulse Biosciences Q4 revenue rises q-o-q

Pulse Biosciences

19/02/2026 21:30

Overview

Bioelectric medicine firm's Q4 revenue rises q-o-q to $264 thousand

GAAP net loss for Q4 narrows to $17.4 mln compared to last year

Company received FDA approval for pivotal IDE study in Q4

Outlook

Pulse Biosciences plans to complete pivotal enrollment in cardiac programs by 2026

Company expanding IDE site activation to support patient enrollment completion in 2026

Pulse Biosciences did not provide specific revenue or EPS guidance in press release

Result Drivers

ATRIAL FIBRILLATION STUDY - Achieved 100% procedural success in atrial fibrillation treatment with nPulse Cardiac Catheter System, as highlighted in feasibility study

COMMERCIAL LAUNCH - Generated $264 thousand in revenue from controlled commercial launch of soft tissue ablation technology

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q4 Net Income
-$17.43 mln
Q4 Income from Operations
-$18.25 mln


Analyst Coverage

The current average analyst rating on the shares is "strong buy" and the breakdown of recommendations is 2 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

The average consensus recommendation for the advanced medical equipment & technology peer group is "buy."

Wall Street's median 12-month price target for Pulse Biosciences Inc is $26.00, about 2.1% above its February 18 closing price of $25.46

Press Release: ID:nBw3GSwnsa

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)